Most launch delays don’t start in the clinic—they stem from overlooked gaps in commercial compliance. Complete Response Letters (CRLs), though one of the greatest threats to launch success, are largely preventable with the proper commercial compliance framework.
What You’ll Learn in this POV:
- Why 70% of launches fail
- The most common gaps cited in FDA-issued CRLs
- Critical differences between clinical and commercial compliance
- Why fragmented vendors create compliance vulnerabilities
- How EVERSANA’s compliance-first commercialization strategy reduces CRL incidence
- How early commercial compliance integration reduces costly delays, protects launch timelines, and maximizes asset value
Ensure commercial readiness before submission, not after rejection.
Author
Vikram’s experience includes more than 20 years of leading global teams and building successful partnerships with top life sciences companies and health authorities around the globe. He has a strong background in digital technology…
Jimmy, Vice President of Business Development at EVERSANA, brings seasoned experience in basic, translational, and clinical research across the executive, strategic, operational, and managerial levels. He is an expert clinical and business developer with…